KindredBio Leadership

Richard Chin, MD

Richard Chin, MD

Founder and Chief Executive Officer

Richard Chin is a Harvard-trained physician and a former Rhodes Scholar with a track record of almost a dozen drug approvals and over 50 INDs. Richard has developed several drugs for immune diseases, including Lucentis®, Xolair®, Tysabri®, and Rituxan®. These products have yielded over $10 billion in sales per year.

Previously, Richard was Head of Clinical Research for the Biotherapeutics Unit at Genentech, where he oversaw Genentech’s drug development programs; Senior VP of Global Development at Elan; CEO of Oxigene, a NASDAQ-listed biotechnology company; and CEO of OneWorld Health, a Gates Foundation-funded nonprofit developing drugs for impoverished patients in developing countries. In 2006, BusinessWeek named Richard one of 99 youngest public company CEOs in the United States. He has authored several major textbooks on clinical development and teaches drug development at UCSF.

Denise Bevers

Denise Bevers

Founder and Chief Operating Officer

Denise Bevers is an expert in clinical operations, medical affairs, and scientific communications. Denise has over 20 years of pharmaceutical and research experience, and has managed dozens of products and development programs from Phase I through Phase IV. She was previously at Elan Pharmaceuticals, Scripps Clinic and Research Foundation, Quintiles, and SkyePharma. Most recently, she was President and Founding Partner of SD Scientific, a full-service medical affairs and communications company.

Hangjun Zhan, PhD

Hangjun Zhan, PhD

Chief Scientific Officer

Dr. Zhan is a highly regarded protein biochemist and biophysicist with 20 years of drug discovery experience in the biotechnology industry. He joined KindredBio in February 2014 to lead our biologics research. Most recently, Dr. Zhan served as an Executive Member at Aragen Biosciences and led their protein sciences group. Prior to that, Dr. Zhan established and led the Protein Biochemistry Group at Exelixis, including Protein Expression, Fermentation/Bioproduction, Protein Purification/Biophysics, and Proteomics. His team’s work led to more than 20 drug candidates. Prior to that, Dr. Zhan was Group Leader of Protein Chemistry at Axys Biopharmaceuticals (Celera), where he managed a fermentation group and a protein biochemistry group. Dr. Zhan completed his post-doctoral training in Dr. John Collier’s lab at Harvard Medical School, where he applied in-depth biophysics to elucidate dynamic protein structural changes in solution and in membrane. While earning his Ph.D. from the University of Washington, he discovered a novel chemical-signaling molecule involved in bacterial invasion.

Wendy Wee

Wendy Wee

Chief Financial Officer

Wendy Wee is a financial executive with over 30 years of public company experience in both the biotechnology and high-technology industries. From 2002 to 2014, Wendy served in various positions at Telik a biotechnology company focused on oncology, including Vice President of Finance, Principal Financial and Accounting Officer, and Controller. Prior to Telik, she was the Senior Director of Finance and Controller at Connetics, Inc., a biotechnology company focused on dermatological diseases. Previous to that she held various management positions at Silicon Graphics, Inc., MIPS Computer Systems and Unisys Corporation.

Karen Greenwood

Karen Greenwood

Vice President of Project Management

Karen Greenwood has 30 years of experience in Animal Health drug discovery and development. She is a biochemist by training, with 15 years of laboratory experience in screen design and development. She previously worked at Pfizer Animal Health, Zoetis and Parnell, giving her broad experience across companion animal and livestock projects and both small molecules and monoclonal antibodies. Karen is familiar with all stages of the drug discovery process, from idea to proof of concept, clinical studies, regulatory submission, launch and marketing. She is particularly proud of her work on Apoquel and Cytopoint for atopic dermatitis in dogs.

Katja Buhrer

Katja Buhrer

Vice President of Corporate Development and Investor Relations

Katja Buhrer has a diverse background in investor relations advisory, capital markets and financial reporting. For the past seven years, she was Managing Director at the investor relations consultancy, MBS Value Partners. In this role, Katja devised and executed investor relations programs for the firm’s clients, and oversaw their investment community communications. Previously, Katja worked at Citi in capital markets, and sales and trading. She was also a reporter, editor and columnist at the Australian Financial Review. During this time, Katja was a frequent author of front page stories, reported on Australia’s largest companies and had a personal weekly capital markets column.

Melinda Poole O’Banion, DVM

Melinda Poole O’Banion, DVM

Executive Director of Clinical Development and Regulatory Affairs

Melinda Poole O’Banion is an equine internal medicine trained specialist. She trained in an ACVIM and ABVP residency program at Mississippi State University College of Veterinary Medicine where she also served as clinical teaching faculty for 2 years. Post academia, she transitioned into the animal health industry in clinical research and development working on novel drugs for dogs, cats and horses. Melinda was previously at Boehringer Ingelheim Vetmedica, Elanco Animal Health, and Dechra Veterinary Products. She was the key clinical development member for Prascend® (pergolide mesylate) for horses and Osphos® (clodronate injection) for horses. Melinda has 14 years of animal health industry experience developing drugs for animals; she has worked on numerous small molecules for dogs, cats and horses in early and late stage development.

Jenna Hahn

Jenna Hahn

Senior Director, Commercial

Specializing in the companion animal and equine industries, Jenna Hahn has over 15 years of sales, marketing, and product launch experience. Jenna has worked in the veterinary division of Hill’s Pet Nutrition and Merck and for animal health companies such as Merial and IDEXX. She has consulted for many small businesses in the pet and equine industry, helping to bring their products to the veterinary market. She currently sits on the Board of Directors for the Northern California Association of Equine Practitioners. Jenna is very active in the veterinary community, where she has spent her career working directly with veterinarians and their staff to help improve the quality of life for the animals we love.

Kathy Vannatta

Kathy Vannatta

Senior Director, Regulatory Affairs

Kathy Vannatta has over 20 years of experience in animal health regulatory affairs and research and development. She previously worked at Elanco Animal Health where she was a proven leader and regulatory professional supporting both companion and food animal development. She has gained key product approvals with both the FDA and EPA. Kathy is experienced with mergers and acquisitions and has expert knowledge in global regulatory affairs transition strategies. She is passionate about how regulatory affairs can enable innovation that allows dogs, cats and horses to live longer, healthier lives.

Valentine S. Williams DVM, MS, DACVS

Valentine S. Williams DVM, MS, DACVS

Director of Veterinary Affairs

Valentine Williams is a board certified equine surgeon with extensive experience in academia, private equine practice and the animal health industry. She started her veterinary career serving in multi-disciplinary private equine practices with a heavy focus on sports medicine, lameness, and surgery. She specialized in equine orthopedic and soft tissue surgery, as well as equine reproduction, routine care, emergency care, internal medicine, and neonatal care. She has a broad and diverse animal health background serving Fort Dodge Animal Health and Ceva Animal Health in technical services, marketing and sales support, pre-approval drug development, post-approval life cycle management, pharmacovigilance, and regulatory. Her experience spans both the companion animal (dogs/cats and horses) and food animal (cattle) sector. Her diverse background in the animal pharmaceutical and biological industry is unique and allows her to support veterinarians in many roles. She has a passion for education and bringing science to the practice of veterinary medicine.